O inibidor Btk Ibrutinib limita o desenvolvimento da endometriose em camundongos

In: Universidade de São Paulo · 2021 · doi:10.11606/t.5.2021.tde-28102021-134952 · W3208619609
dissertation OA: gold CC0
📄 Open PDF View on OpenAlex View at publisher
AI-generated summary by claude@2026-06, 2026-06-06

Ibrutinib, a BTK inhibitor, was shown to limit endometriosis development in a mouse model by suppressing the growth and inflammatory response of peritoneal macrophages.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-06

This dissertation studies whether pharmacologic inhibition of Bruton’s tyrosine kinase (Btk) with ibrutinib affects the development of endometriosis-like lesions in mice, using an established murine model with in vivo treatment of operated animals. The work uses measures including ultrasound-based assessment of implant size, histology, and mechanistic readouts such as RT-qPCR, flow cytometry of spleen and peritoneal cells, and cytokine quantification by ELISA. A stated limitation is that, as a thesis, the study is constrained to its specific animal model, endpoints, and experimental design rather than direct human validation. This paper is centrally about endometriosis — it tests whether ibrutinib limits endometriosis development in mice.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A big thanks to Cristina, for her

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK